Nyxoah (NYXH)
Commercializes a leadless, battery-free therapy for obstructive sleep apnea.
Something off on this page? Send us feedback.
Commercializes Genio, a leadless, battery-free hypoglossal-neurostimulation therapy for obstructive sleep apnea. Its single-product business moved from European sales to early U.S. commercialization after FDA approval.
Commercializes Genio, a leadless, battery-free hypoglossal-neurostimulation therapy for obstructive sleep apnea. The system is designed as a single-incision, patient-centered therapy and is the company’s core product, rather than part of a broad device portfolio.
European commercialization followed CE Mark certification, with first German sales preceding the U.S. launch. FDA approval for a subset of adults with moderate-to-severe OSA enabled U.S. commercial activity, while the ordinary shares remain listed in both Brussels and on Nasdaq. The business is therefore shaped by Genio’s regulatory status and the execution of an early U.S. commercialization effort.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 6, 2026 | Robert W. Baird | Target | Target: $2.85 | Target: $2.31 |
| Aug 6, 2026 | Oppenheimer | Target | Target: $15 | Target: $4 |
| Jul 9, 2026 | Robert W. Baird | Target | Target: — | Target: $2.85 |
| Jun 17, 2026 | Stifel Nicolaus | Target | Target: $5 | Target: $3 |
| May 13, 2026 | Piper Sandler | Reiterate | Rating: —Target: $9 | Target: $7 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $112.0M · Total debt $60.2M · Total assets $192.9M · Shareholders' equity $95.2M
- Revenue
- $8.8M
- Operating income
- −$23.6M
- Net income
- −$37.7M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 22.10% | 22.12M shares | |
|---|---|---|---|
| 45 holders · as of Jun 30, 2026 | |||
| Other | 77.90% | 77.96M shares | |
| remainder | |||
100.07M company shares as of Sep 13, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Aigh Capital Management LLCInstitution | 14.52% | 14.53M | as of Jun 30, 2026 |
BNP Paribas Asset Management Holding S.A.Institution | 0.96% | 962,524 | as of Jun 30, 2026 |
Blackstone Inc.Institution | 0.92% | 921,500 | as of Jun 30, 2026 |
Axxion S.A.Institution | 0.90% | 904,895 | as of Jun 30, 2026 |
Vestal Point Capital, LPInstitution | 0.84% | 843,461 | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Inspire Medical Systems
Implantable hypoglossal stimulation for moderate-to-severe OSA
- LivaNova
FDA-approved proximal hypoglossal stimulation for moderate-to-severe OSA
- ResMed
PAP therapy for OSA across sleep and breathing health
- Five Point
OSA masks and CPAP systems in home respiratory care
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Nyxoah | $1.40 | 0.00% | $148.1M | — | — | 5.7 | +455.6% |
| Inspire Medical Systems | $71.87 | +0.87% | $2.19B | 16.4 | 54.8 | 2.4 | −7.6% |
| LivaNova | $78.49 | +0.08% | $4.29B | 23.1 | 17.8 | 2.9 | +10.8% |
| ResMed | $221.97 | 0.00% | $32.44B | 21.5 | 18.2 | 5.7 | +8.6% |
| Five Point | $4.92 | −0.40% | $349.8M | 14.1 | — | 3.0 | +157.8% |
| Median | 18.9 | 18.2 | 3.0 | +9.7% |